NasdaqGS - Nasdaq Real Time Price USD

Day One Biopharmaceuticals, Inc. (DAWN)

Compare
15.16 +0.15 (+1.00%)
As of 2:27 PM EDT. Market Open.
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
8,192.00
--
--
--
--
--
Operating Expense
300,014.00
206,064.00
146,909.00
72,743.00
13,782.00
--
Operating Income
-292,529.00
-206,064.00
-146,909.00
-72,743.00
-13,782.00
--
Net Non Operating Interest Income Expense
--
--
4,746.00
4.00
-30.00
-2,077.00
Other Income Expense
126,601.00
17,147.00
4,728.00
-11.00
-30,031.00
--
Pretax Income
-165,928.00
-188,917.00
-142,181.00
-72,754.00
-43,843.00
--
Net Income Common Stockholders
-167,480.00
-188,917.00
-142,181.00
-170,639.00
-40,507.00
--
Diluted NI Available to Com Stockholders
-167,480.00
-188,917.00
-142,181.00
-170,639.00
-40,507.00
--
Basic EPS
-1.94
-2.37
-2.17
-4.62
-0.96
--
Diluted EPS
-1.94
-2.37
-2.17
-4.62
-0.96
--
Basic Average Shares
86,465.99
79,773.00
65,466.77
36,960.57
42,030.98
--
Diluted Average Shares
86,465.99
79,773.00
65,466.77
36,960.57
42,030.98
--
Total Operating Income as Reported
-292,529.00
-206,064.00
-146,909.00
-72,743.00
-13,782.00
--
Total Expenses
300,721.00
206,064.00
146,909.00
72,743.00
13,782.00
--
Net Income from Continuing & Discontinued Operation
-167,480.00
-188,917.00
-142,181.00
-70,645.00
-40,507.00
--
Normalized Income
-186,122.00
-206,104.00
-146,927.00
-70,649.00
-10,507.00
--
Interest Expense
--
--
--
--
30.00
2,077.00
Net Interest Income
--
--
4,746.00
4.00
-30.00
-2,077.00
EBIT
-292,529.00
-206,064.00
-146,909.00
-72,743.00
-13,782.00
--
EBITDA
-291,803.00
-205,681.00
-146,378.00
-72,544.00
-13,627.00
--
Reconciled Depreciation
726.00
383.00
531.00
199.00
155.00
--
Net Income from Continuing Operation Net Minority Interest
-167,480.00
-188,917.00
-142,181.00
-70,645.00
-40,507.00
--
Total Unusual Items Excluding Goodwill
18,642.00
17,187.00
4,746.00
4.00
-30,000.00
--
Total Unusual Items
18,642.00
17,187.00
4,746.00
4.00
-30,000.00
--
Normalized EBITDA
-310,445.00
-222,868.00
-151,124.00
-72,548.00
16,373.00
--
12/31/2019 - 5/27/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers